Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Lanying Du · NEW YORK BLOOD CENTER · 2020 · $839,218 — Project Summary Viral subunit vaccines are safe and convenient, but generally suffer low efficacy. Our overall hypothesis is that an intrinsic limitation is associated with subunit vaccine designs in which artificially exposed surfaces of subunit vaccines contain epitopes unfavorable for vaccine eff…
Dawn Caster · UNIVERSITY OF LOUISVILLE · 2020 · $165,780 — DESCRIPTION (provided by applicant): Up to 60% of SLE patients develop clinical evidence of kidney injury, termed lupus nephritis (LN). LN is thought to be caused by glomerular immune complex deposition activating an inflammatory cascade that injures glomerular cells, leading to proteinuria and…
Erik S Welf · UT SOUTHWESTERN MEDICAL CENTER · 2020 · $116,100 — DESCRIPTION (provided by applicant): A greater understanding of the mechanisms mediating melanoma metastasis is necessary for treatment of advanced disease. Because all melanoma cells must move through and survive in non-native tissue microenvironments during metastatic dissemination, the abili…
Ananth V Annapragada · BAYLOR COLLEGE OF MEDICINE · 2020 · $156,621 — An understanding of the transplacental transport of the SARS-CoV-2 virion is of enormous importance. Objective characterization of virion transport, even in animal models, is a hugely challenging task. Using transplacental transport as an example, we seek to address this problem: we will design and …
Matthias Johannes Schnell · THOMAS JEFFERSON UNIVERSITY · 2020 · $429,000 — Abstract The recently emerged coronavirus SARS-CoV-2, the causative agent of COVID-19, is rapidly spreading in the world with over 4,8 million cases, and 320,000 deaths as of May 16, 2020. This novel coronavirus is thought to have emerged from a live animal market in Wuhan, China. It has quickly spr…
SHOHEI KOIDE · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2020 · $466,125 — ABSTRACT The goal of this project is to establish an accurate and sensitive method for predicting the neutralization capacity against SARS-CoV-2 of serum samples by deep mining of antibody profiles. The COVID-19 pandemic remains a global threat with nearly seven million cases and 400K deaths. In the…
CHRISTOPHER C. W. HUGHES · UNIVERSITY OF CALIFORNIA-IRVINE · 2020 · $179,153 — PROJECT SUMMARY COVID19 is caused by SARS-CoV-2, a novel member of the human coronavirus family that includes the closely related SARS-CoV (SARS) and MERS-CoV (MERS) viruses. SARS-CoV-2 viral spike protein binds to human angiotensin converting enzyme-2 (ACE2) on the surface of cells and is then prim…
Vaughn Vasil Smider · APPLIED BIOMEDICAL SCIENCE INSTITUTE · 2020 · $358,581 — Vaccines are the primary means by which to prevent, control, or eradicate infectious diseases. While many vaccines have been successfully developed and have resulted in enormous medical and veterinary benefit, there are certain viruses that have eluded effective vaccine development. Generally, virus…
Michel C Nussenzweig · ROCKEFELLER UNIVERSITY · 2020 · $400,050 — The WHO and US authorities have declared a public health emergency over the recent outbreak of a new coronavirus (CoV) originating from Wuhan, China (nCoV-2019, recently renamed SARS-CoV-2 and responsible for causing the coronavirus disease termed COVID-2019). The discovery of human monoclonal antib…
Margaret M Stratton · UNIVERSITY OF MASSACHUSETTS AMHERST · 2020 · $89,039 — PROJECT SUMMARY How does a memory outlast the lifetime of the molecule that encodes it? More than two decades ago, Francis Crick had the foresight to speculate that perhaps a multimeric protein could serve as a molecular memory by sharing its activation state with newly synthesized proteins through …
ASHLEY M. DEACON · ACCELERO BIOSTRUCTURES, INC. · 2020 · $486,536 — The novel SARS coronavirus (SARS-CoV-2) global pandemic has taken a strong foothold and it is estimated that it will infect hundreds of millions of people, with millions dying. These estimates underscore the severity of the COVID-19 disease, caused by SARS-CoV-2, yet there are currently no effective…
Matthew Reed Steinhart · INDIANA UNIVERSITY INDIANAPOLIS · 2020 · $37,163 — ABSTRACT Neurofibromatosis Type 2 (NF2) is a genetic condition in which specific types of tumors form in various locations throughout the body. Though the majority of these tumors grow slowly, the location of certain tumors can cause significant dysfunction. One of these tumor types grows on the ves…
Lynda Coughlan · UNIVERSITY OF MARYLAND BALTIMORE · 2020 · $420,520 — SUMMARY: The emergence of the SARS-CoV-2 coronavirus (CoV) highlighted our lack of preparedness, and has emphasized the importance of rapidly building capacity in the development of reagents, tools, diagnostics and therapeutics for SARS-CoV-2 and related CoVs with pandemic potential. An immediate go…
Jonathan W Yewdell · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $490,071 — We have generated Sleeping Beauty transposase vectors that drive expression of the SARS-CoV-2 receptor ACE2 and or protease TMPRSS2 in host cells and use these vectors to create permanent transfected lines of A549, 293FT, and BHK-21 cells. We have generated a recombinant vesicular stomatitis virus t…
Mark Connors · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $109,107 — Our laboratory is engaged in the study of the immune response to SARS-CoV-2 in two major areas. The first of these is the study of the immune response to natural infection. The second is the response to virus-like particles or replicating recombinant adenovirus type 4 vaccines. We are collaborato…
Patrick Duffy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $576,660 — LMIV produced and obtained antigens for multiple COVID-19 serology assays. First, plasmids were obtained for production of full-length spike and RBD used in the assay developed by Florian Krammer at Mount Sinai Hospital in New York. After 3 successful production runs of COVID-19 spike proteins used…
Niraj Tolia · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $100,000 — SARS-CoV-2 is a serious global threat that has been met with an unparalleled research response. Scientific understanding of SARS-CoV-2 is already deeper than most pathogens and it is growing rapidly. This knowledge provides an opportunity to design a vaccine that goes beyond traditional methods. …
JOHN H KEHRL · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $45,608 — Recombinant SARS-CoV-2 spike protein was made in CHO and HEK293F cells and purified by affinity chromatography. To modify the glycosylation of the spike protein CHO cells were treated with Kifunesin, an inhibitor of class I -mannosidases. This prevents the trimming of mannose residues on glycoprotei…
Mitchell Ho · DIVISION OF BASIC SCIENCES - NCI · 2020 · $416,151 — In FY20, Dr Ho has evaluated the current status and challenges for developing antibody therapeutics targeting SARS-Cov-2 and wrote a review/perspective article [Ho Antibody Therapeutics 2020; PMID: 32566896]. SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-…
eric freed · DIVISION OF BASIC SCIENCES - NCI · 2020 · $232,377 — In a structural and functional analysis of the SARS-CoV-2 spike protein that we recently started, we have obtained preliminary data indicating that that MARCH8, but not a catalytically inactive MARCH8 mutant, targets the spike proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2 for degradation. We also d…